Latest news with #KeshavBiyani
Fashion Network
12-05-2025
- Business
- Fashion Network
The Good Bug raises Rs 100 crore in funding round
Nutraceutical consumer startup The Good Bug has raised Rs 100 crore ($11.8 million) in new funding from Susquehanna Asia VC along with participation from existing investor Fireside Ventures. The company will utilise the funds to expand its reach, hiring, research & development, and marketing. Commenting on the funding, Keshav Biyani, co-founder of The Good Bug in a statement said, 'This new capital infusion will be pivotal in accelerating our research and development efforts, driving groundbreaking innovations in gut health through rigorous R&D. Additionally, we will bolster our marketing and distribution strategies to enhance consumer awareness and expand our reach across India. Attracting top-tier talent across research, technology, science, and business will further strengthen our foundation.' Bhavani Rana, investment advisor to Susquehanna Asia VC added, 'What sets TGB apart is the strength of its leadership team and their exceptional ability to execute on their vision. With strong momentum and a clear strategy, the company is well positioned to capitalize on the macro tailwinds of India's rapidly expanding nutraceuticals market.' Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, The Good Bug offers wellness products across various categories.
Entrepreneur
07-05-2025
- Business
- Entrepreneur
Susquehanna, Fireside Back The Good Bug in INR 100 Cr Round to Power Gut Health Science
The Mumbai-based startup will deploy the fresh capital towards ramping up R&D in microbiome science, scaling clinical trials, expanding its distribution footprint, and boosting brand awareness among consumers and healthcare professionals. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Gut health startup The Good Bug has raised INR 100 crore (approximately USD 12 million) in its Series B funding round led by Susquehanna Asia Venture Capital, the investment arm of Susquehanna International Group. Existing backer Fireside Ventures also participated in the round. The Mumbai-based startup will deploy the fresh capital towards ramping up R&D in microbiome science, scaling clinical trials, expanding its distribution footprint, and boosting brand awareness among consumers and healthcare professionals. "This partnership with Susquehanna Asia VC, combined with the continued support from Fireside Ventures and others, is a powerful endorsement of our mission to transform health outcomes through gut bacterial science," said Keshav Biyani, Co-founder of The Good Bug. "This new capital infusion will accelerate our innovations, strengthen distribution, and attract top-tier talent in research and business." Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, The Good Bug aims to simplify gut health through science-backed, honest, and transparent solutions. The startup offers an extensive range of gut wellness products, including clinically tested synbiotic formulas, probiotics, prebiotic fibers, and its flagship 14-day Detox formula. Its newest "Ferments" collection includes kombuchas, water kefirs, and fermented pickles. All products are formulated for both adults and children, combining natural ingredients with scientifically validated bacterial strains to support digestive and overall health. The company's latest launch, the Advanced Metabolic System, has caught the attention of healthcare professionals for its cutting-edge application of natural GLP-1 science. This clinically tested innovation helps regulate appetite, reduce gut inflammation, and sustainably manage weight—offering a science-driven alternative in the weight management space. Bhavani Rana, Investment Advisor at Susquehanna Asia VC, noted, "We are thrilled to invest in The Good Bug. Their leadership, deep scientific approach, and consumer-first strategy uniquely position them to lead India's evolving nutraceuticals landscape." Ankur Khaitan, Principal at Fireside Ventures, added, "We've seen the impact of The Good Bug's purpose-led innovation and are excited to deepen our long-term partnership." With total funding now reaching USD 20 million, The Good Bug is poised to drive category-defining change in India's digestive wellness sector and scale its impact across the country's growing health-conscious population.
&w=3840&q=100)
Business Standard
06-05-2025
- Business
- Business Standard
The Good Bug raises ₹100 crore to scale gut health R&D and reach
Gut health-focused start-up The Good Bug (TGB) has raised ₹100 crore in a new funding round led by Susquehanna Asia VC, with participation from existing investor Fireside Ventures. The capital will be used to expand the company's research and development capabilities, strengthen marketing and distribution, and hire talent across research, technology and business functions. Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, TGB offers a range of synbiotics, probiotics, prebiotics, detox products, and fermented items such as kombucha and kefir. Its products are positioned to address issues related to digestion, obesity and women's wellness, using microbiome and gut bacterial science. This is the largest funding round for the company to date, following a $4 million (₹35 crore) Series A extension round in 2024 led by Sharrp Ventures, the family office of Marico Group Chairman Harsh Mariwala. Fireside Ventures led the company's original Series A round in 2023. TGB claims over one million customers across India and has recently launched a new product in the weight management segment — the 'Advanced Metabolic System' — which the company says uses natural ingredients to elevate GLP-1 levels and reduce chronic gut inflammation. Keshav Biyani, Co-founder of The Good Bug, said the funding will help scale the firm's R&D efforts and increase consumer reach. Bhavani Rana, Investment Advisor to Susquehanna Asia VC, said the firm sees potential in TGB's microbiome-based approach to digestive health and cited India's growing nutraceuticals market as a key growth driver. Fireside Ventures Principal Ankur Khaitan said the investor remains committed to the company's long-term strategy. TGB's latest round comes amid rising global interest in microbiome science and a broader consumer shift towards preventive health solutions.
